[{"address1": "320 Lorimer Street", "address2": "Unit 2", "city": "Port Melbourne", "state": "VIC", "zip": "3207", "country": "Australia", "phone": "61 3 8681 4050", "fax": "61 3 8681 4099", "website": "https://polynovo.com", "industry": "Medical Devices", "sector": "Healthcare", "longBusinessSummary": "PolyNovo Limited designs, manufactures, and sells biodegradable medical devices in the United States, Australia, New Zealand, and internationally. The company offers NovoSorb Biodegradable Temporising Matrix, a dermal scaffold for the regeneration of the dermis when lost through extensive surgery, trauma, or burn. It is also developing hernia devices for hernia repair and solution for ventral hernia and complex abdominal wall reconstruction; NovoSorb Dermal Beta Cell, a novel intracutaneous ectopic pancreas to treat type 1 diabetes; NovoSorb MTX for single stage grafting in burns, chronic, and surgical wounds; and plastics and reconstructive device products. The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was incorporated in 1998 and is headquartered in Port Melbourne, Australia.", "fullTimeEmployees": 254, "companyOfficers": [{"maxAge": 1, "name": "Mr. Swami  Raote BPHARM, M.B.A.", "title": "CEO & Director", "fiscalYear": 2024, "totalPay": 513250, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jan-Marcel  Gielen C.A.", "title": "Chief Financial Officer", "fiscalYear": 2024, "totalPay": 252464, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David  McQuillan Ph.D.", "title": "Chief Technical & Scientific Officer", "fiscalYear": 2024, "totalPay": 266475, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Philip  Scorgie", "title": "Chief Information Officer", "fiscalYear": 2024, "totalPay": 187052, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ahmed  Hassan", "title": "Director of Operations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Lior  Harel", "title": "General Counsel & Company Secretary", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Ingrid  Anderson", "title": "Chief People Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Edward  Graubart", "title": "President of North America", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Joseph F. Amaral M.D.", "age": 67, "title": "Chief Medical Officer", "yearBorn": 1956, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. David N. Morris BAppSc, BBus", "title": "President of Asia Pacific", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 9, "boardRisk": 9, "compensationRisk": 9, "shareHolderRightsRisk": 1, "overallRisk": 9, "governanceEpochDate": 1725148800, "compensationAsOfEpochDate": 1735603200, "maxAge": 86400, "priceHint": 4, "previousClose": 1.58, "open": 1.58, "dayLow": 1.58, "dayHigh": 1.58, "regularMarketPreviousClose": 1.58, "regularMarketOpen": 1.58, "regularMarketDayLow": 1.58, "regularMarketDayHigh": 1.58, "beta": 1.669, "trailingPE": 160.0, "volume": 6000, "regularMarketVolume": 6000, "averageVolume": 1693, "averageVolume10days": 1490, "averageDailyVolume10Day": 1490, "bid": 1.65, "ask": 1.75, "bidSize": 40000, "askSize": 40000, "marketCap": 1105107200, "fiftyTwoWeekLow": 0.513, "fiftyTwoWeekHigh": 1.74, "priceToSalesTrailing12Months": 10.705499, "fiftyDayAverage": 1.62208, "twoHundredDayAverage": 1.32053, "currency": "USD", "enterpriseValue": 1073795456, "profitMargins": 0.05096, "floatShares": 607149435, "sharesOutstanding": 690691968, "heldPercentInsiders": 0.113350004, "heldPercentInstitutions": 0.15897, "bookValue": 0.104, "priceToBook": 15.384615, "lastFiscalYearEnd": 1719705600, "nextFiscalYearEnd": 1751241600, "mostRecentQuarter": 1719705600, "netIncomeToCommon": 5261000, "trailingEps": 0.01, "enterpriseToRevenue": 10.402, "enterpriseToEbitda": 407.203, "exchange": "PNK", "quoteType": "EQUITY", "symbol": "CALZF", "underlyingSymbol": "CALZF", "shortName": "Polynovo Ltd.", "longName": "PolyNovo Limited", "firstTradeDateEpochUtc": 1610116200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "8b1cbdd5-f3ba-31d9-8766-3ece232d066c", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.6, "recommendationKey": "none", "totalCash": 45957000, "totalCashPerShare": 0.067, "ebitda": 2637000, "totalDebt": 15380000, "quickRatio": 2.868, "currentRatio": 3.411, "totalRevenue": 103228000, "debtToEquity": 21.324, "revenuePerShare": 0.15, "returnOnAssets": 0.00557, "returnOnEquity": 0.076519996, "freeCashflow": -1456000, "operatingCashflow": 3683000, "revenueGrowth": 0.545, "grossMargins": 0.84105, "ebitdaMargins": 0.02555, "operatingMargins": 0.01831, "financialCurrency": "AUD", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]